# A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

> **NCT05905133** · PHASE2 · UNKNOWN · sponsor: **Connect Biopharm LLC** · enrollment: 360 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** CBP-201

## Key facts

- **NCT ID:** NCT05905133
- **Lead sponsor:** Connect Biopharm LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-15
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905133, "A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05905133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*